ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Contractile effects of dulaglutide in the human atrium.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dulaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist. Dulaglutide (LY2189265) is a GLP-1(7-37) analogue fused by a linker to a modified immunoglobulin G. GLP-1R agonists like dulaglutide can be used to treat diabetes type 2 and obesity. We tested the hypothesis that dulaglutide directly increased force of contraction in the human heart via GLP-1R. To this end, we conducted contraction experiments in paced (1 Hz) isolated human right atrial muscle preparations (HAP). HAP were obtained during open-heart surgery from adult patients with severe coronary heart disease. We detected a concentration- and time-dependent positive inotropic effect of dulaglutide in HAP. Dulaglutide augmented the rate of tension development, the rate of tension relaxation and accelerated the relaxation time in HAP. Dulaglutide (100 nM) augmented the phosphorylation state of phospholamban at serine 16 and the phosphorylation state of the inhibitory subunit of troponin. The positive inotropic effect of 100 nM dulaglutide in HAP was attenuated by 100 nM exendin (9-39). In contrast, dulaglutide alone or in the presence of phosphodiesterase inhibitor rolipram up to 100 nM failed to exert a positive inotropic effect in isolated electrically paced (1 Hz) mouse left atrial preparations and did not increase the beating rate of spontaneously beating mouse right atrial preparations. Our data suggest that dulaglutide raised force of contraction in the isolated paced human atrium via GLP-1R involving cAMP-dependent protein kinase in HAP.
Indexed as
Identifiers
42380521What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.